CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 414 enrolled
Drug / intervention
Galcanezumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02163993
NCT02163993Phase 2Completed
CompareCT.gov

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients With Episodic Migraine

Eli Lilly and Company·interventional·Posted Jun 16, 2014·Updated Nov 23, 2018

In Brief

A Phase 2 clinical trial evaluating Galcanezumab and Placebo for Migraine Headache. Completed, enrolled 414 participants across 40 sites.

Detailed Summary

The main purpose of this study is to evaluate whether the study drug known as galcanezumab is safe and effective in the prevention of migraine headaches.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Headache
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 16, 2014
Enrollment StartJul 7, 2014
Primary CompletionAug 19, 2015
Study CompletionFeb 12, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 12.0 years ago

Interventions

Galcanezumabdrug

Administered SQ

Placebodrug

Administered SQ